Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 7Skin Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Glioblastoma 4Diabetes Mellitus, Insulin-Dependent, 12 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Advanced Cancer 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

cemiplimab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Non-Small Cell Lung Carcinoma × Ipilimumab × Clear all
NCT03430063 2022-11-03

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 2 Terminated
28 enrolled 16 charts
Thoracic

Advanced Non-Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡